BioSpace News Archive

Vifor Fresenius Medical Care Renal Pharma announced that the European Medicines Agency’s CHMP has recommended approval of Tavneos® in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis with polyangiitis or microscopic polyangiitis, the two main forms of ANCA-associated vasculitis.

Hansa Biopharma announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General Meeting on May 12, 2021 and has the following composition.

GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that clinical data of LUMEVOQ® and GS030 gene therapies will be presented at the 125th Annual Meeting of the American Academy of Ophthalmology in New Orleans, Louisiana.

Nanoform, an innovative nanoparticle medicine enabling company, announced it has received ISO/IEC 27001:2013 certification for its Information Security Management System.

BD, a leading global medical technology company, will begin its Investor Day at 8 a.m. ET to share how it plans to leverage the breadth and depth of its core portfolio to fuel a new wave of growth through transformative solutions that can help reinvent health care.

Clearday, Inc. (OTCQB: CLRD) today announced a Joint venture with Invento Research Inc., an ISO 9001:2015 certified company, to bring the latest robotic technology to the senior care world.

PLx Pharma Inc. announced today certain financial and operational results for the three and nine months ended September 30, 2021.

Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, will present translational data from the Phase 1 SURPASS trial during the poster session at the Society for Immunotherapy of Cancer (SITC) annual meeting in Washington, D.C. (or virtual) (Abstract #373) from November 12-14, 2021.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, reported financial results for the third quarter ended September 30, 2021.

Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that three posters with preclinical data of its innate cell engagers (ICE®) are presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).